MENU
Aim higher

VACIMMUNE

Generation & optimization of anti-FCGR2B antibodies to create tolerizing vaccines for autoimmune diseases and severe allergy

The aim of the current project is to achieve Proof of Principle for the use of fully human agonistic antibodies targeted at the antibody binding receptor FCGR2B for use in tolerizing vaccines, using Multiple Sclerosis as a model.
Acronym: 
VACIMMUNE
Project ID: 
5 307
Ranking: 
16
Cut-off: 
3
Start date: 
01-03-2010
Project Duration: 
36months
Project costs: 
1 740 090.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic